Pulmonary Cell News Volume 4.49 | Dec 17 2015

    0
    13
    Pulmonary Cell News 4.49 December 17, 2015

    Pulmonary Cell News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook   PULCN on Twitter

     
    TOP STORY
    TRIM72 Modulates Caveolar Endocytosis in Repair of Lung Cells
    Researchers showed that in primary type I alveolar epithelial cells, lack of tripartite motif protein 7 (TRIM72) led to significant reduction of caveolin 1 at the plasma membrane, accompanied by marked attenuation of caveolar endocytosis. [Am J Physiol Lung Cell Mol Physiol] Abstract
    Model the Human Respiratory Epithelium with PneumaCultâ„¢-ALI. Click to View Data.

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    In Vitro Systems Toxicology Assessment of a Candidate Modified Risk Tobacco Product Shows Reduced Toxicity Compared to a Conventional Cigarette
    Scientists investigated the biological impact of a candidate modified risk tobacco product, the tobacco-heating system 2.2, compared to the 3R4F reference cigarette in normal primary human bronchial epithelial cells. [Chem Res Toxicol] Abstract

    Cold Stress Increases Reactive Oxygen Species Formation via TRPA1 Activation in A549 Cells
    Researchers measured the changes of reactive oxygen species (ROS) and the cytosolic Ca2+ concentration ([Ca2+]c) in A549 cells. They observed that cold stress exposure of A549 cell resulted in an increase of ROS and [Ca2+]c, which was completely attenuated by removing Ca2+ from medium. [Cell Stress Chaperones] Abstract

    Cyclic Mechanical Stretch Down-Regulates Cathelicidin Antimicrobial Peptide Expression and Activates a Pro-Inflammatory Response in Human Bronchial Epithelial Cells
    Scientists showed that treatment of VA10 cells with vitamin D3 and/or 4-phenyl butyric acid counteracted cyclic stretch mediated down-regulation of cathelicidin antimicrobial peptide mRNA and protein expression. [PeerJ] Full Article

    LUNG CANCER

    A Novel Naphthalimide Compound Restores p53 Function in Non-Small-Cell Lung Cancer by Reorganizing the Bak-Bcl-xl Complex and Triggering Transcriptional Regulation
    NA-17 showed p53-dependent inhibition selectivity in different non-small-cell lung cancer cell lines due to the activation state of endogenous p53 in the background level. Further studies revealed that NA-17 caused cell cycle arrest at the G1 phase, changed cell size, induced apoptosis and cell death by increasing the proportion of sub-G1 cells. [J Biol Chem] Abstract | Full Article

    In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation through RAD51 Regulation
    Investigators demonstrated that miR-34a directly binds to the 3’ untranslated region of RAD51 and regulates homologous recombination, inhibiting double-strand-break repair in non-small-cell lung cancer cells. [Mol Ther Nucleic Acids] Full Article

    A Spontaneous Metastasis Model Reveals the Significance of Claudin-9 Overexpression in Lung Cancer Metastasis
    Scientists developed a spontaneous metastasis model that retains the egression step of metastasis. By repeated in vivo passaging of the poorly metastatic Lewis lung carcinoma cells, they generated a cell line that readily metastasizes to lungs and liver from subcutaneous tumors. [Clin Exp Metastasis] Abstract

    Γ-Ionizing Radiation-Induced Activation of the EGFR–p38/ERK–STAT3/CREB-1–EMT Pathway Promotes the Migration/Invasion of Non-Small Cell Lung Cancer Cells and Is Inhibited by Podophyllotoxin Acetate
    Researchers report a new intracellular signaling pathway involved in γ-ionizing radiation (IR)-induced migration/invasion and show that podophyllotoxin acetate inhibits the IR-induced invasion and migration of A549 cells. [Tumor Biol] Abstract

    Rap2b Promotes Proliferation, Migration, and Invasion of Lung Cancer Cells
    The authors investigated the effect of Rap2b on the lung cancer malignant phenotype, such as cell proliferation and metastasis. They found that Rap2b could promote the abilities of lung cancer cell wound healing, migration, and invasion via increasing matrix metalloproteinase-2 enzyme activity. [J Recept Signal Transduct Res] Abstract

    Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video

     
    REVIEWS
    Respiratory Effects of Sulfur Mustard Exposure, Similarities and Differences with Asthma and COPD
    Sulfur mustard (SM) is highly toxic to the respiratory system, leading to hacking cough, rhinorrhea, chest tightness, acute pharyngitis and laryngitis, chronic bronchitis and lung fibrosis. The authors provide an updated summary of information on SM exposures and their differences with asthma and COPD. [Inhal Toxicol] Abstract

    Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

     
    SCIENCE NEWS
    Amoebas Reveal How Human Airway Cells Rally against Cigarette Smoke Damage
    Despite its prevalence and ongoing research into chronic obstructive pulmonary disease, there is no cure, current treatments are largely palliative, and new treatment targets are scarce. Now Corrine Kliment and colleagues in Doug Robinson’s lab at Johns Hopkins University have found two new targets in a surprising place—amoebas. [Press release from The American Society for Cell Biology (ASCB) discussing research presented at ASCB 2015, San Diego] Press Release

    From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.

     
    INDUSTRY NEWS
    FDA Grants Roche’s Alecensa (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer
    Roche announced that the US Food and Drug Administration (FDA) granted accelerated approval to Alecensa® for the treatment of people with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. [F. Hoffmann-La Roche Ltd.] Press Release

    Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase Ib Trial In Genetically Selected Patients
    Mirati Therapeutics, Inc. announced that the first patient with non-small cell lung cancer has been dosed in a Phase Ib clinical trial of MGCD516. [Mirati Therapeutics, Inc.] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW ELCC 2016 European Lung Cancer Conference
    April 13-16, 2016
    Geneva, Switzerland

    Visit our events page to see a complete list of events in the pulmonary cell community.

     
    JOB OPPORTUNITIES
    NEW Professor – Precision Cancer Medicine (German Cancer Research Center)

    PhD Positions – Heart and Lung Research (Max Planck Institute for Heart and Lung Research)

    Postdoctoral Positions – Lung Cancer Research (University of Texas)

    Postdoctoral Scientist (Bioinformatician) – Clinical and Experimental Pharmacology (Cancer Research UK Manchester Institute)

    PhD Studentships – Cancer and Allergy (University of Salzburg)

    Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

    Postdoctoral Fellow – Cancer Biology (Cold Spring Harbor Laboratory)

    Postdoctoral Positions – Fibrotic Remodeling of the Lung (University of Vermont)

    Postdoctoral Positions – Cancer (University of Texas MD Anderson Cancer Center)

    Post-Doctoral Fellow – Lung Microbiome Research and Asthma (University of Michigan)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Pulmonary Cell News: Archives | Events | Contact Us